{"transactions":[{"id":2288139,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Options (right to buy)","published_at":"2022-04-29T17:11:53.000Z","date":"2022-03-17","kind":"other","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Mr. Cearnal passed away on March 17, 2022.  All unvested equity awards forfeited upon death."}],"balance_after":0,"derivative":{"exercise_price":3.22,"exercise_date":"2025-03-17","expiration_date":"2031-03-17","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-026154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122026154/doc4.xml","form_type":"4"}},{"id":2288138,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-04-29T17:11:53.000Z","date":"2022-03-17","kind":"other","acquired":false,"shares":15000,"price":2.74,"value":41100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Mr. Cearnal passed away on March 17, 2022.  All unvested equity awards forfeited upon death."}],"balance_after":163473,"source":{"system":"sec-edgar","filing":"0001209191-22-026154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122026154/doc4.xml","form_type":"4"}},{"id":2440489,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-20","kind":"purchase","acquired":true,"shares":314,"price":4.33,"value":1359.62,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":178473,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440488,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-17","kind":"purchase","acquired":true,"shares":240,"price":4.17,"value":1000.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":178159,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440487,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-16","kind":"purchase","acquired":true,"shares":240,"price":4.53,"value":1087.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":177919,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440486,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-15","kind":"purchase","acquired":true,"shares":200,"price":4.29,"value":858.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":177679,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440485,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-14","kind":"purchase","acquired":true,"shares":200,"price":4.28,"value":856.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":177479,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440484,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-13","kind":"purchase","acquired":true,"shares":200,"price":4.36,"value":872.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":177279,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440483,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-10","kind":"purchase","acquired":true,"shares":90,"price":4.82,"value":433.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":177079,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440482,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-09","kind":"purchase","acquired":true,"shares":90,"price":5.81,"value":522.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176989,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440481,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-08","kind":"purchase","acquired":true,"shares":90,"price":6.15,"value":553.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176899,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440480,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-07","kind":"purchase","acquired":true,"shares":90,"price":5.61,"value":504.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176809,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440479,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":90,"price":4.46,"value":401.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176719,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440478,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-03","kind":"purchase","acquired":true,"shares":90,"price":4.47,"value":402.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176629,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440477,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-02","kind":"purchase","acquired":true,"shares":90,"price":3.84,"value":345.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176539,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2440476,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-01-07T22:07:04.000Z","date":"2021-12-01","kind":"purchase","acquired":true,"shares":90,"price":4.14,"value":372.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176449,"source":{"system":"sec-edgar","filing":"0001209191-22-002447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919122002447/doc4.xml","form_type":"4"}},{"id":2486875,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-30","kind":"purchase","acquired":true,"shares":175,"price":4.61,"value":806.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176359,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486874,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-29","kind":"purchase","acquired":true,"shares":175,"price":2.23,"value":390.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176184,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486873,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-26","kind":"purchase","acquired":true,"shares":175,"price":2.26,"value":395.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":176009,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486872,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-24","kind":"purchase","acquired":true,"shares":175,"price":2.31,"value":404.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175834,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486871,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-23","kind":"purchase","acquired":true,"shares":105,"price":2.29,"value":240.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175659,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486870,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-22","kind":"purchase","acquired":true,"shares":105,"price":2.35,"value":246.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175554,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486869,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-19","kind":"purchase","acquired":true,"shares":105,"price":2.55,"value":267.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175449,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486868,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-18","kind":"purchase","acquired":true,"shares":105,"price":2.58,"value":270.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175344,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486867,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-17","kind":"purchase","acquired":true,"shares":105,"price":2.58,"value":270.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175239,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486866,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-16","kind":"purchase","acquired":true,"shares":105,"price":2.66,"value":279.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175134,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486865,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-15","kind":"purchase","acquired":true,"shares":105,"price":2.71,"value":284.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":175029,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486864,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-12","kind":"purchase","acquired":true,"shares":105,"price":2.67,"value":280.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174924,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486863,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-11","kind":"purchase","acquired":true,"shares":105,"price":2.83,"value":297.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174819,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486862,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-10","kind":"purchase","acquired":true,"shares":105,"price":2.94,"value":308.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174714,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486861,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-09","kind":"purchase","acquired":true,"shares":105,"price":3.21,"value":337.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174609,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486860,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-08","kind":"purchase","acquired":true,"shares":105,"price":2.95,"value":309.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174504,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486859,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-05","kind":"purchase","acquired":true,"shares":105,"price":2.71,"value":284.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174399,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486858,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-04","kind":"purchase","acquired":true,"shares":105,"price":2.73,"value":286.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174294,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486857,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-03","kind":"purchase","acquired":true,"shares":105,"price":2.71,"value":284.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174189,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486856,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-02","kind":"purchase","acquired":true,"shares":105,"price":2.63,"value":276.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":174084,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2486855,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-12-03T22:05:36.000Z","date":"2021-11-01","kind":"purchase","acquired":true,"shares":105,"price":2.67,"value":280.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173979,"source":{"system":"sec-edgar","filing":"0001209191-21-067878","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121067878/doc4.xml","form_type":"4"}},{"id":2523472,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-29","kind":"purchase","acquired":true,"shares":105,"price":2.72,"value":285.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173874,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523471,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-28","kind":"purchase","acquired":true,"shares":105,"price":2.61,"value":274.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173769,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523470,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-27","kind":"purchase","acquired":true,"shares":105,"price":2.61,"value":274.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173664,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523469,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-26","kind":"purchase","acquired":true,"shares":105,"price":2.64,"value":277.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173559,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523468,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-25","kind":"purchase","acquired":true,"shares":105,"price":2.64,"value":277.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173454,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523467,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-22","kind":"purchase","acquired":true,"shares":105,"price":2.66,"value":279.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173349,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523466,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-21","kind":"purchase","acquired":true,"shares":105,"price":2.65,"value":278.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173244,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523465,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-20","kind":"purchase","acquired":true,"shares":105,"price":2.63,"value":276.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173139,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523464,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-19","kind":"purchase","acquired":true,"shares":105,"price":2.76,"value":289.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":173034,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523463,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-18","kind":"purchase","acquired":true,"shares":105,"price":2.75,"value":288.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172929,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523462,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-15","kind":"purchase","acquired":true,"shares":105,"price":2.76,"value":289.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172824,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523461,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-14","kind":"purchase","acquired":true,"shares":105,"price":2.81,"value":295.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172719,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523460,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-13","kind":"purchase","acquired":true,"shares":105,"price":2.71,"value":284.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172614,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523459,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-12","kind":"purchase","acquired":true,"shares":105,"price":2.71,"value":284.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172509,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523458,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-11","kind":"purchase","acquired":true,"shares":105,"price":2.73,"value":286.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172404,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523457,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-08","kind":"purchase","acquired":true,"shares":105,"price":2.84,"value":298.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172299,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523456,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-07","kind":"purchase","acquired":true,"shares":105,"price":2.76,"value":289.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172194,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523455,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-06","kind":"purchase","acquired":true,"shares":105,"price":2.76,"value":289.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":172089,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523454,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-05","kind":"purchase","acquired":true,"shares":105,"price":2.82,"value":296.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171984,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523453,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-04","kind":"purchase","acquired":true,"shares":105,"price":2.87,"value":301.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171879,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2523452,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-11-05T21:15:11.000Z","date":"2021-10-01","kind":"purchase","acquired":true,"shares":105,"price":2.69,"value":282.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171774,"source":{"system":"sec-edgar","filing":"0001209191-21-063217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121063217/doc4.xml","form_type":"4"}},{"id":2554926,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-30","kind":"purchase","acquired":true,"shares":105,"price":2.72,"value":285.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171669,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554925,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-29","kind":"purchase","acquired":true,"shares":105,"price":2.82,"value":296.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171564,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554924,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-28","kind":"purchase","acquired":true,"shares":105,"price":2.76,"value":289.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171459,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554923,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-27","kind":"purchase","acquired":true,"shares":105,"price":2.79,"value":292.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171354,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554922,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-24","kind":"purchase","acquired":true,"shares":105,"price":2.74,"value":287.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171249,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554921,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-23","kind":"purchase","acquired":true,"shares":105,"price":2.75,"value":288.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171144,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554920,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-22","kind":"purchase","acquired":true,"shares":105,"price":2.76,"value":289.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":171039,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554919,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-21","kind":"purchase","acquired":true,"shares":105,"price":2.81,"value":295.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170934,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554918,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-20","kind":"purchase","acquired":true,"shares":105,"price":2.82,"value":296.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170829,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554917,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":105,"price":2.85,"value":299.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170724,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554916,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-16","kind":"purchase","acquired":true,"shares":105,"price":2.91,"value":305.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170619,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554915,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-15","kind":"purchase","acquired":true,"shares":105,"price":2.86,"value":300.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170514,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554914,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":105,"price":3.02,"value":317.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170409,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554913,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-13","kind":"purchase","acquired":true,"shares":105,"price":2.96,"value":310.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170304,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554912,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":105,"price":2.78,"value":291.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170199,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554911,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-09","kind":"purchase","acquired":true,"shares":105,"price":2.77,"value":290.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":170094,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554910,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-08","kind":"purchase","acquired":true,"shares":105,"price":2.89,"value":303.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169989,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554909,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-07","kind":"purchase","acquired":true,"shares":105,"price":2.79,"value":292.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169884,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554908,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-03","kind":"purchase","acquired":true,"shares":105,"price":2.85,"value":299.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169779,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554907,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-02","kind":"purchase","acquired":true,"shares":105,"price":2.88,"value":302.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169674,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2554906,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-10-01T21:07:04.000Z","date":"2021-09-01","kind":"purchase","acquired":true,"shares":105,"price":2.88,"value":302.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169569,"source":{"system":"sec-edgar","filing":"0001209191-21-058506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121058506/doc4.xml","form_type":"4"}},{"id":2573572,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-31","kind":"purchase","acquired":true,"shares":105,"price":2.93,"value":307.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169464,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573571,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-30","kind":"purchase","acquired":true,"shares":105,"price":2.88,"value":302.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169359,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573570,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-27","kind":"purchase","acquired":true,"shares":105,"price":2.84,"value":298.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169254,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573569,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-26","kind":"purchase","acquired":true,"shares":105,"price":2.82,"value":296.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169149,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573568,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-25","kind":"purchase","acquired":true,"shares":105,"price":2.79,"value":292.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":169044,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573567,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-24","kind":"purchase","acquired":true,"shares":105,"price":2.89,"value":303.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168939,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573566,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-23","kind":"purchase","acquired":true,"shares":105,"price":2.87,"value":301.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168834,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573565,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-20","kind":"purchase","acquired":true,"shares":105,"price":2.96,"value":310.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168729,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573564,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-19","kind":"purchase","acquired":true,"shares":105,"price":3.02,"value":317.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168624,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573563,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":105,"price":2.97,"value":311.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168519,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573562,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":105,"price":3.05,"value":320.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168414,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573561,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":105,"price":2.92,"value":306.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168309,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573560,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-13","kind":"purchase","acquired":true,"shares":105,"price":2.92,"value":306.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168204,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573559,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-11","kind":"purchase","acquired":true,"shares":105,"price":2.98,"value":312.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":168099,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573558,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-10","kind":"purchase","acquired":true,"shares":105,"price":2.96,"value":310.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":167994,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573557,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-09","kind":"purchase","acquired":true,"shares":105,"price":2.93,"value":307.65,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":167889,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573556,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-06","kind":"purchase","acquired":true,"shares":105,"price":3.01,"value":316.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":167784,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573555,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-05","kind":"purchase","acquired":true,"shares":105,"price":3.11,"value":326.55,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":167679,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573554,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-04","kind":"purchase","acquired":true,"shares":105,"price":3.18,"value":333.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":167574,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573553,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-03","kind":"purchase","acquired":true,"shares":105,"price":3.17,"value":332.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":167469,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}},{"id":2573552,"issuer":{"id":6757,"kind":"organization","name":"CUMBERLAND PHARMACEUTICALS INC"},"owners":[{"id":127762,"kind":"person","name":"Cearnal Martin E","position":1,"cik":"0001408500","reported_name":"Cearnal Martin E","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr VP/Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2021-09-10T21:03:46.000Z","date":"2021-08-02","kind":"purchase","acquired":true,"shares":105,"price":3.34,"value":350.7,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021."}],"balance_after":167364,"source":{"system":"sec-edgar","filing":"0001209191-21-055478","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087294/000120919121055478/doc4.xml","form_type":"4"}}],"next_cursor":"2021-09-10T21:03:46.000000Z,2573552"}